Bicara Therapeutics (BCAX) shares plunged 44% after the company said late Thursday that updated interim data from its Phase 1/1b trial of ficerafusp alfa with pembrolizumab in patients with first-line recurrent/metastatic head and neck squamous cell carcinoma showed a 64% objective response rate, including several complete responses. Median overall survival and duration of response were not yet reached as of the December 2024 data cutoff.
More than 5.19 million shares traded intraday compared with a daily average of about 588,000.
Deckers Outdoor's (DECK) strong fiscal Q4 results were overshadowed by sales growth deceleration at its Hoka sneaker brand and potential demand weakness from price increases, prompting KeyBanc Capital Markets to downgrade the footwear and apparel company's stock.
Shares of Deckers sank 18% following an increase in intraday trading volume to over 13.9 million from a daily average of about 3.2 million.
Ross Stores (ROST) overnight warned that elevated tariffs could pressure profitability, noting that over half its merchandise originates from China despite limited direct imports. Citing ongoing macroeconomic uncertainty and shifting trade policies, the company withdrew its full-year sales and earnings guidance.
Shares declined 10%, with intraday trading volume rising to over 13.1 million versus a daily average of about 3.2 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.